VIVA BIOTECH's incubated enterprise investment received a merger and acquisition with a maximum cost of 47 million USD

阿斯達克財經網
2025.12.14 11:28

維亞生物 (01873.HK) 公佈，公司持股 3.14% 的 Arthrosi Therapeutics 獲 Sobi US Holding Corp.透過併購方式收購，協議預付款 9.5 億美元及或然代價不超過 5.5 億美元。集團預期收到首筆付款約 3,000 萬美元及或然代價不超過 1,700 萬美元，估計變現公平值收益約 400 萬美元。

完成後，公司不再持有 Arthrosi Therapeutics 任何股權，其為臨牀階段的生物技術公司。

Source: 阿斯達克財經網 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.